EN|About Us
About Us

About Us

About Us

Home>About Us>About Us

China Resources Pharmaceutical Group Limited (CR Pharma) (Stock Code: 3320.HK) is a leading integrated pharmaceutical company in China specializing in the manufacturing, distribution, and retail of medicines and nutraceutical products. Since the Company went public, it has introduced a number of important capital market indexes, including Hang Seng Composite LargeCap Index, FTSE Global Large Cap Index, Morgan Stanley Capital International (MSCI) China Index, Hang Seng Stock Connect Hong Kong Index, etc. 

We have many subsidiaries, including China Resources Pharmaceutical Commercial Group Co., Ltd. (CR Pharma Comm), China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu, Stock Code: 000999.SZ), China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane, Stock Code: 600062.SH), China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (CR Jiangzhong), Dong-E-E-Jiao Pharmaceutical Co., Ltd. (Dong-E-E-Jiao, Stock Code: 000423.SZ), China Resources Zizhu Pharmaceutical Co., Ltd. (CR Zizhu), China Resources Biopharmaceutical Co., Ltd., The National Institutes of Pharmaceutical R&D Co., Ltd., China Resources Care Co., Ltd. (CR Care), etc. 

In 2020, CR Pharmaceutical generated a revenue of HK$ 200.423 billion and a total profit of HK$ 5.324 billion. 

As the largest manufacturer of non-prescription drugs in China, CR Pharmaceutical engage in the R&D, manufacturing, and distribution of pharmaceutical products. Our products include chemical drugs, traditional Chinese medicine, biological drugs and supplements, which cover a wide range of treatment fields, including the cardiovascular system, digestive tracts, metabolism, large-volume intravenous infusion, pediatrics, the respiratory system, etc. In addition, we own multiple well-known brands, such as CR Sanjiu, Dong-E-E-Jiao, CR Double-Crane, CR Jiangzhong, and Levonorgestrel Tablets (Yu Ting). 

We operate a national distribution network formed by 176 logistics centers covering 28 provinces, municipalities and autonomous regions. With comprehensive product supply channels and an extensive distribution network, we directly distribute our products to Chinese hospitals and other medical institutions. Our retail pharmacy network of 862 self-operated retail pharmacies and 194 DTP pharmacies, which is one of the largest pharmacy networks in China, include a number of national and regional premium brand names, such as “CR Care (华润堂),” “Yibaoquanxin (医保全新),” “Li’an chain (礼安连锁),” and “Tung Tak Tong (同德堂).” We also created TECK SOON HONG, a professional retail pharmacy brand. Based on the platform of TECK SOON HONG, we establish a system that integrates the distribution of prescription drugs and value-added services, such as online prescription dispensing, door-to-door drug delivery, medical consultation and health management services.  

“Protecting human health and improving quality of life” is the lofty mission of CR Pharmaceutical. Based on the opportunities brought by the development and reform of China’s pharmaceutical and healthcare industry, we actively explore the core areas and links of the industrial chain and insist on innovation-driven development. Giving full play to the synergies created by our integrated business structure, we optimize the allocation of resources, strengthen international cooperation, promote transformation and upgrading, and continue to improve our core competitiveness, striving to become a leader in China’s pharmaceutical and health industry. 

Back to Top